BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Despite $9B Setback, Eli Lilly Boldly Moves on With Five New Alzheimer’s Candidates

  During a fireside chat at BIO in San Diego earlier this summer, Daniel Skovronsky confirmed Eli Lilly’s commitment to finding an effective therapy for ALZ’s disease.

  October 26, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Bio NC

  3 Small-Cap Biotechs With the Most Promising New Antibiotics in Clinical Trials

  New antibiotic development seems to go through cycles and many large companies have stayed away from antibiotics or abandoned efforts, despite a growing need for new antibiotics.

  October 26, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  Teva Makes Move to Block Eli Lilly From Bringing Its Migraine Drug to the U.S.

  Teva said Lilly’s planned drug would infringe five patents that cover its own migraine drug, which it sought U.S. Food and Drug Administration approval for on Oct. 16.

  October 26, 2017

   · 

  1 min read
• 

  Business

  Gilead HCV Woes Continue and Investors are Spooked

  Gilead continues to see serious revenue declines in its hepatitis C marketshare, a space it has dominated for several years.

  October 26, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Biotech Beach

  Impact Biomedicines’ High-Risk Gamble on Failed Sanofi Drug Gains $90M Financing

  Impact Biomedicines closed on a $90M structured financing with Oberland Capital.

  October 26, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  BlueRock Therapeutics Sets Up HQ in Cambridge, Expands Executive Team

  BlueRock was founded in 2016 when Versant Ventures and Bayer invested $225 million in a Series A financing.

  October 26, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Glaxosmithkline to Build New Drug Testing Facility in Europe

  Drug giant calls for clarity on Brexit and a minimum two-year transition period to avoid disruption to medical supplies.

  October 26, 2017

   · 

  1 min read
• 

  Drug Development

  AbbVie Touts Late-Stage Psoriasis Drug Trial Data

  AbbVie said its Phase III drug risankizumab is more effective than its own blockbuster drug Humira or J&J’s Stelara for psoriasis patients.

  October 26, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  FDA Calls BioMarin’s Hemophilia A Drug a Breakthrough

  BioMarin announced that the FDA granted its valoctocogene roxaparvovec for Hemophilia A Breakthrough Therapy Designation.

  October 26, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Bio NC

  2 Biotech Stocks to Buy for the Next Generation

  Future generations might look back and wish their parents and grandparents had added these three top stocks to their portfolios today.

  October 26, 2017

   · 

  1 min read